How AI is Unlocking the Human Microbiome

Outpost Bio Co-Founder and CEO Jenny Yang joined Brian Chee on HumanifAI HealthTech to talk about why the microbiome may be a missing layer in understanding why patients respond differently to drugs—and how combining human-derived microbiome experiments with AI could help make drug development more predictive and personalized.

The conversation covers:

• Why clinical trial failure rates remain stubbornly high despite decades of progress in genomics and drug discovery

• How the gut microbiome adds biological diversity that human DNA alone cannot explain

• How Outpost’s Lab-in-the-Loop platform combines wet lab experiments with machine learning to generate causal data on microbiome–compound interactions

• Why modeling drug metabolism across diverse microbial communities could help predict efficacy and side effects before costly clinical trials

• How Jenny’s background in clinical machine learning, algorithmic fairness, and bias mitigation shapes Outpost’s approach to building more reliable biological models

Tune in on

Apple Podcasts

Spotify

YouTube

…or wherever you listen to podcasts.